Alendronate sodium/vitamin D3 for senile patients with osteoporosis after total hip arthroplasty

doi:10.3969/j.issn.2095-4344.2017.15.002

Abstract

Abstract:

BACKGROUND: Adverse events following total hip arthroplasty are commonly seen in elderly osteoporotic patients, especially prosthetic loosening caused by reduced bone density surrounding the prosthesis, which even needs reversion.

OBJECTIVE: To investigate the effectiveness and safety of alendronate sodium/vitamin D3 for total hip arthroplasty in elderly patients with osteoporosis.

METHODS: Seventy-four patients with osteoporosis were randomized to experimental and control groups (n=37 per group), and both received total hip arthroplasty, followed by the calcium supplementary treatment at 1-2 weeks. Meanwhile, the patients in the experimental group were orally given alendronate sodium/vitamin D3 (70 mg), once weekly. The course was 6 months in both two groups.

RESULTS AND CONCLUSION: In the experimental group, the bone mineral density of the lumbar vertebrae and contralateral hip were significantly increased at 3, 6 and 12 months postoperatively compared with baseline, and also significantly higher than those in the control group (P < 0.05). (2) The incidence of aseptic loosening and prosthesis adjacent fracture did not differ significantly between two groups (P > 0.05). (3) The serum levels of creatinine, phosphorus and calcium all kept in normal values at baseline and 3, 6 and 12 months postoperatively in both two groups, and showed no significant differences before and after treatment between two groups (P > 0.05). (4) These findings indicate that alendronate sodium/vitamin D3 can effectively increase the bone mineral density of elderly osteoporotic patients after total hip arthroplasty free of significant adverse effects, and exposes no effect on renal function and calcium-phosphorus metabolism.

中国组织工程研究杂志出版内容重点：人工关节；骨植入物；脊柱；骨折；内固定；数字化骨科；组织工程

Key words: Tissue Engineering, Hip Joint, Bone Density

CLC Number:

R318

Huang Fei-qi, Zhao Xiao, Yao Nai-jie, Chen Yan-mei. Alendronate sodium/vitamin D3 for senile patients with osteoporosis after total hip arthroplasty[J]. Chinese Journal of Tissue Engineering Research, 2017, 21(15): 2303-2307.

Figures/Tables 5

References

[1] Shanb AA, Youssef EF. The impact of adding weight-bearing exercise versus nonweight bearing programs to the medical treatment of elderly patients with osteoporosis. J Family Community Med. 2014;21(3):176-181.

[2] Wei D, Jung J, Yang H, et al. Nanotechnology Treatment Options for Osteoporosis and Its Corresponding Consequences. Curr Osteoporos Rep. 2016;14(5):239-247.

[3] Kemmler W, Bebenek M, Kohl M, et al. Exercise and fractures in postmenopausal women. Final results of the controlled Erlangen Fitness and Osteoporosis Prevention Study (EFOPS). Osteoporos Int. 2015;23(10):1267-1276.

[4] Yi Z, Bin S, Jing Y, et al. Tranexamic acid administration in primary total hip arthroplasty: a randomized controlled trial of intravenous combined with topical versus single-dose intravenous administration. J Bone Joint Surg Am. 2016;98(12):983-991.

[5] Rahman WA, Vial TA, Hetaimish B, et al. Outcome of revision total hip arthroplasty in management of failed metal-on-metal hip arthroplasty. J Arthroplasty. 2016;31(11):2559-2563.

[6] 陈顺兴,陈福友.注射用骨肽联合阿仑膦酸钠治疗骨质疏松症的临床疗效[J].中国现代药物应用,2015,9(15):16-18.

[7] 周萍,胡红,郭明军,等.补肾壮骨汤联合针灸及阿仑膦酸钠治疗骨质疏松症的临床研究[J].实用医学杂志, 2015,31(22):3663-3665.

[8] 骆阳,张柳,宋亚琪,等.阿仑膦酸钠可抑制骨质疏松性骨折的愈合[J].中国组织工程研究, 2011,15(37):6841-6845.

[9] Li X, Guo D, Shi G, et al. Role of total hip replacement arthroplasty between transplantation and acute kidney injury. Ren Fail. 2014;36(6):899-903.

[10] Reichert JC, Volkmann MR, Koppmair M, et al. Comparative retrospective study of the direct anterior and transgluteal approaches for primary total hip arthroplasty. Int Orthop. 2015;39(12):2309-2313.

[11] Jr LA, Berend KR, Morris MJ, et al. Large-diameter metal-on-metal total hip arthroplasty: dislocation infrequent but survivorship poor. Clin Orthop Relat Res. 2015;473(2): 509-520.

[12] Higgins BT, Barlow DR, Heagerty NE, et al. Anterior vs. posterior approach for total hip arthroplasty, a systematic review and meta-analysis. J Arthroplasty. 2015;30(3): 419-434.

[13] Yan Y, Hu J, Lu H, et al. Genetic susceptibility to total hip arthroplasty failure: a case-control study on the influence of MMP 1 gene polymorphism. Diagn Pathol. 2014;9(1):1-5.

[14] Boot W, Moojen DJ, Visser E, et al. Missed low-grade infection in suspected aseptic loosening has no consequences for the survival of total hip arthroplasty: 173 patients followed for 6 to 9 years. Acta Orthop. 2015;6(6):1-6.

[15] Gallo J, Vaculova J, Goodman SB, et al. Contributions of human tissue analysis to understanding the mechanisms of loosening and osteolysis in total hip replacement. Acta Biomater. 2014;10(6):2354-2366.

[16] Solomon DH, Johnston SS, Boytsov NN, et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29(9):1929-1937.

[17] Klop C, Gibsonsmith D, Elders PJM, et al. Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010. Osteoporos Int. 2015;26(7):1919-1928.

[18] Wang J, Wang Y, Liu WD, et al. Hip fractures in Hefei, China: the Hefei osteoporosis project. J Bone Miner Metab, 2014; 32(2):206-214.

[19] Antonelli M, Einstadter D, Magrey M. Screening and treatment of osteoporosis after hip fracture: comparison of sex and race. J Clin Densitom. 2014;17(4):479-483.

[20] 黄公怡.骨质疏松性骨折诊疗指南[C].中华医学会第四次全国骨质疏松和骨矿盐疾病学术会议论文汇编, 2006.

[21] 邱贵兴,裴福兴,胡侦明,等.中国骨质疏松性骨折诊疗指南(骨质疏松性骨折诊断及治疗原则)[J].中国骨与关节外科, 2015,8(5): 371-374.

[22] 温志刚,梁志繁,詹国强,等.阿仑膦酸钠与阿法骨化醇治疗老年性骨质疏松症的疗效比较[J].现代医院,2014,14(1):38-40.

[23] 苏凡,林静霞,吴利秋,等.阿仑膦酸钠与激素替代疗法治疗骨质疏松症的比较[J].中国组织工程研究,2016,20(46):6893-6898.

[24] Berkhout J, Stone JA, Verhamme KM, et al. Disease systems analysis of bone mineral density and bone turnover markers in response to alendronate, placebo, and washout in postmenopausal women. CPT Pharmacometrics Syst Pharmacol. 2016;5(12):656-664.

[25] 肖佛义,张庆,林东红.阿仑膦酸钠维D3与阿仑膦酸钠治疗骨质疏松症的效果对比[J].中外医疗,2015, (9):135-136.

[26] 梁碧彦,钟伟湘,李尚,等.评价阿仑膦酸钠联合注射用骨肽及碳酸钙D3片治疗骨质疏松症的疗效及安全性[J].中国现代药物应用, 2015,9(9):112-113.

[27] Salazar M, Hernandes L, Ramos AL, et al. Effect of alendronate sodium on tooth movement in ovariectomized rats. Arch Oral Biol. 2015;60(5):776-781.

[28] 刘煊文.不同剂量阿仑膦酸钠维D3片对老年骨质疏松患者的治疗效果[J].中国老年学杂志,2014,34(9):2340-2342.

[29] 钱雪丰,曹平,刘拴,等.阿托伐他汀联合鲑鱼降钙素、碳酸钙D3、阿伦磷酸钠治疗老年骨质疏松症的疗效观察[J].中国医院用药评价与分析,2016,16(6):793-795.

[30] 张新玉,魏丽.不同药物对绝经后骨质疏松疗效观察及生活质量和药物经济学评价[J].中国骨质疏松杂志,2011,17(6):517-522.

[31] 张玉辉.阿仑膦酸钠维D_3片治疗骨质疏松的临床应用效果观察[J].海峡药学,2015,27(2):142-143.